HomeComparePREUF vs MRK

PREUF vs MRK: Dividend Comparison 2026

PREUF yields 10.21% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $7.9K in total portfolio value· pulled ahead in Year 3
10 years
PREUF
PREUF
● Live price
10.21%
Share price
$0.14
Annual div
$0.01
5Y div CAGR
-36%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$13.64
Full PREUF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — PREUF vs MRK

📍 MRK pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPREUFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PREUF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PREUF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PREUF
Annual income on $10K today (after 15% tax)
$867.76/yr
After 10yr DRIP, annual income (after tax)
$11.59/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $796.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PREUF + MRK for your $10,000?

PREUF: 50%MRK: 50%
100% MRK50/50100% PREUF
Portfolio after 10yr
$26.8K
Annual income
$481.97/yr
Blended yield
1.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PREUF
No analyst data
Altman Z
0.5
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PREUF buys
0
MRK buys
0
No recent congressional trades found for PREUF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPREUFMRK
Forward yield10.21%3.25%
Annual dividend / share$0.01$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR-36%8.2%
Portfolio after 10y$22.8K$30.7K
Annual income after 10y$13.64$950.29
Total dividends collected$1.9K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PREUF vs MRK ($10,000, DRIP)

YearPREUF PortfolioPREUF Income/yrMRK PortfolioMRK Income/yrGap
1$11,353$653.37$11,192$351.54+$161.00PREUF
2$12,592$443.69$12,524$392.70+$68.00PREUF
3← crossover$13,768$294.33$14,015$438.65$247.00MRK
4$14,924$192.49$15,682$489.96$758.00MRK
5$16,093$124.80$17,547$547.23$1.5KMRK
6$17,300$80.50$19,632$611.16$2.3KMRK
7$18,563$51.76$21,963$682.53$3.4KMRK
8$19,896$33.22$24,571$762.18$4.7KMRK
9$21,310$21.30$27,486$851.08$6.2KMRK
10$22,815$13.64$30,745$950.29$7.9KMRK

PREUF vs MRK: Complete Analysis 2026

PREUFStock

Prosperity REIT [SEHK: 808] is a Hong Kong collective investment scheme authorized under section 104 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Prosperity REIT owns a diverse portfolio of seven high-quality properties in the decentralized business districts of Hong Kong, comprising all, or a portion of, three Grade A office buildings, one commercial building, two industrial/office buildings and one industrial building, with a total gross rentable area of about 1.28 million sq. ft.

Full PREUF Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this PREUF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PREUF vs SCHDPREUF vs JEPIPREUF vs OPREUF vs KOPREUF vs MAINPREUF vs JNJPREUF vs ABBVPREUF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.